GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000697920 | Oral cavity | OSCC | response to oxidative stress | 273/7305 | 446/18723 | 8.35e-22 | 1.65e-19 | 273 |
GO:190495119 | Oral cavity | OSCC | positive regulation of establishment of protein localization | 196/7305 | 319/18723 | 2.89e-16 | 2.20e-14 | 196 |
GO:005122219 | Oral cavity | OSCC | positive regulation of protein transport | 187/7305 | 303/18723 | 7.37e-16 | 5.49e-14 | 187 |
GO:001604917 | Oral cavity | OSCC | cell growth | 268/7305 | 482/18723 | 6.55e-14 | 3.51e-12 | 268 |
GO:007048219 | Oral cavity | OSCC | response to oxygen levels | 200/7305 | 347/18723 | 1.17e-12 | 5.13e-11 | 200 |
GO:000155816 | Oral cavity | OSCC | regulation of cell growth | 228/7305 | 414/18723 | 1.74e-11 | 6.09e-10 | 228 |
GO:000166619 | Oral cavity | OSCC | response to hypoxia | 177/7305 | 307/18723 | 2.21e-11 | 7.50e-10 | 177 |
GO:003629319 | Oral cavity | OSCC | response to decreased oxygen levels | 182/7305 | 322/18723 | 1.14e-10 | 3.41e-09 | 182 |
GO:004854520 | Oral cavity | OSCC | response to steroid hormone | 186/7305 | 339/18723 | 1.86e-09 | 4.42e-08 | 186 |
GO:190165419 | Oral cavity | OSCC | response to ketone | 114/7305 | 194/18723 | 1.82e-08 | 3.60e-07 | 114 |
GO:00303079 | Oral cavity | OSCC | positive regulation of cell growth | 92/7305 | 166/18723 | 1.27e-05 | 1.29e-04 | 92 |
GO:00323559 | Oral cavity | OSCC | response to estradiol | 79/7305 | 141/18723 | 3.01e-05 | 2.76e-04 | 79 |
GO:000941018 | Oral cavity | OSCC | response to xenobiotic stimulus | 222/7305 | 462/18723 | 4.00e-05 | 3.48e-04 | 222 |
GO:00325707 | Oral cavity | OSCC | response to progesterone | 26/7305 | 37/18723 | 1.15e-04 | 8.35e-04 | 26 |
GO:001097510 | Oral cavity | OSCC | regulation of neuron projection development | 210/7305 | 445/18723 | 2.35e-04 | 1.52e-03 | 210 |
GO:00075657 | Oral cavity | OSCC | female pregnancy | 98/7305 | 193/18723 | 5.66e-04 | 3.27e-03 | 98 |
GO:000930610 | Oral cavity | OSCC | protein secretion | 169/7305 | 359/18723 | 1.04e-03 | 5.34e-03 | 169 |
GO:003559210 | Oral cavity | OSCC | establishment of protein localization to extracellular region | 169/7305 | 360/18723 | 1.21e-03 | 6.08e-03 | 169 |
GO:00716929 | Oral cavity | OSCC | protein localization to extracellular region | 172/7305 | 368/18723 | 1.40e-03 | 6.79e-03 | 172 |
GO:004592710 | Oral cavity | OSCC | positive regulation of growth | 125/7305 | 259/18723 | 1.44e-03 | 6.97e-03 | 125 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD38 | SNV | Missense_Mutation | | c.857A>T | p.Gln286Leu | p.Q286L | P28907 | protein_coding | deleterious(0) | possibly_damaging(0.641) | TCGA-UB-A7MB-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Targeted Molecular therapy | sorafenib | PD |
CD38 | SNV | Missense_Mutation | | c.524N>G | p.Asp175Gly | p.D175G | P28907 | protein_coding | tolerated(0.29) | benign(0.179) | TCGA-55-5899-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | CR |
CD38 | SNV | Missense_Mutation | | c.659N>A | p.Ser220Asn | p.S220N | P28907 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-21-5782-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CD38 | SNV | Missense_Mutation | | c.363G>T | p.Lys121Asn | p.K121N | P28907 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-37-5819-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
CD38 | SNV | Missense_Mutation | novel | c.419N>C | p.Arg140Pro | p.R140P | P28907 | protein_coding | tolerated(0.17) | possibly_damaging(0.796) | TCGA-85-A50M-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CD38 | SNV | Missense_Mutation | novel | c.551N>A | p.Pro184His | p.P184H | P28907 | protein_coding | deleterious(0.01) | probably_damaging(0.909) | TCGA-96-A4JK-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | gemcitabine | CR |
CD38 | SNV | Missense_Mutation | novel | c.149N>T | p.Trp50Leu | p.W50L | P28907 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CR-7402-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD |
CD38 | SNV | Missense_Mutation | | c.131N>A | p.Pro44Gln | p.P44Q | P28907 | protein_coding | tolerated(0.31) | benign(0.026) | TCGA-CV-7103-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
CD38 | SNV | Missense_Mutation | | c.545N>G | p.Asn182Ser | p.N182S | P28907 | protein_coding | tolerated(0.49) | benign(0.003) | TCGA-CV-7568-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD38 | SNV | Missense_Mutation | novel | c.95T>C | p.Val32Ala | p.V32A | P28907 | protein_coding | tolerated(0.11) | benign(0.051) | TCGA-CV-A45W-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
952 | CD38 | CELL SURFACE, DRUGGABLE GENOME | | CART-38 cells | | |
952 | CD38 | CELL SURFACE, DRUGGABLE GENOME | | CD38-specific gene-engineered T cells | | |
952 | CD38 | CELL SURFACE, DRUGGABLE GENOME | | MOR-202 | | |
952 | CD38 | CELL SURFACE, DRUGGABLE GENOME | antibody | 178103967 | DARATUMUMAB | |
952 | CD38 | CELL SURFACE, DRUGGABLE GENOME | antibody | 252827377 | ISATUXIMAB | |
952 | CD38 | CELL SURFACE, DRUGGABLE GENOME | | CAR-T cells targeting CD38 | | |
952 | CD38 | CELL SURFACE, DRUGGABLE GENOME | | Anti-CD38 CAR-T cells | | |
952 | CD38 | CELL SURFACE, DRUGGABLE GENOME | | CD38 CAR T cells | | |
952 | CD38 | CELL SURFACE, DRUGGABLE GENOME | | SAR650984 | | |
952 | CD38 | CELL SURFACE, DRUGGABLE GENOME | | 4SCAR19 and 4SCAR38 | | |